Overexpression of cyclin D1 is believed to endow mammary epithelial cells (MEC) with a proliferative advantage by virtue of its contribution to pRB inactivation. Accordingly, abrogation of the kinase-dependent function of cyclin D1 is sufficient to render mice resistant to breast cancer initiated by ErbB2. Here, we report that mouse cyclin D1 KE/KE MECs (deficient in cyclin D1 activity) upregulate an autophagy-like process but fail to implement ErbB2-induced senescence in vivo. In addition, immortalized cyclin D1 KE/KE MECs retain high rates of autophagy and reduced ErbB2-mediated transformation in vitro. However, highlighting its dual role during tumorigenesis, downregulation of autophagy led to an increase in senescence in cyclin D1
Introduction
Macroautophagy (referred to hereafter as autophagy) is an evolutionarily conserved and highly regulated catabolic process that involves the sequestration and subsequent lysosomal-mediated degradation of organelles and long-lived proteins (1) . The morphologic hallmark of autophagy is the formation of double-membrane vacuoles, also known as autophagosomes, which transport cytoplasmic cargo to the lysosomes for degradation and substrate recycling (2) . Autophagy-mediated recycling of cellular components provides basic biochemical substrates that can be used for energy production and in biosynthetic reactions, a function that is critical for cell survival in situations of metabolic stress (2) (3) (4) . Nonetheless, in the context of a nutrient-rich environment, basal levels of autophagy are still required to ensure a quality control mechanism that prevents the accumulation of aggregates of proteins and damaged organelles (1, 5) . In addition to these prosurvival functions, there is also evidence that, under certain conditions, autophagy can also be a mechanism of cell death (4, 6) .
Early observations suggested that autophagy acts as a suppressor of tumor formation. For example, Beclin-1/Atg6, a gene essential for the induction of autophagy, was found hemiallelically deleted in 40% to 75% of sporadic breast, ovary, and prostate cancers (7) . In addition, autophagydeficient Beclin-1 þ/À mice show an increased frequency of spontaneous malignancies, indicating that Beclin-1 is a haploinsufficient tumor-suppressor gene (8, 9) . Moreover, indirect evidence for autophagy downregulation during tumorigenesis is provided by the observation that human cancers commonly display an activation of the PI3K/Akt/mTOR pathway, which negatively regulates autophagy (5) . Among the mechanisms that may explain the effects of autophagy on tumorigenesis, autophagy-mediated attenuation of oxidative stress is one of the best studied (5) . Accordingly, autophagydeficient tissues display a protumorigenic phenotype partially as a result of ROS accumulation and increased DNA damage (10) . Recently, a more direct link between autophagy and tumor suppression has been postulated in which autophagy becomes activated during Ras-induced senescence in human fibroblasts (11) . Thus, failure to implement senescence upon inhibition of autophagy may result in the acquisition of a proliferative advantage that accelerates tumor formation (12) . Despite the connection between autophagy and tumor suppression, there is also significant evidence that autophagy is required for proliferation and therapy resistance in established cancers and cancer cell lines (1) . In this scenario, downregulation or inhibition of autophagy leads to an impairment of cell proliferation or enhancement of the therapeutic effect of cancer drugs (13) .
A consistent signature of the luminal-type breast tumors is the overexpression of cyclin D1, a cell-cycle regulator that functionally integrates multiple mitogenic signals, including those derived from tyrosine kinase receptors (14) . It is believed that the oncogenic properties of cyclin D1 depend to a large extent on its ability to activate cyclin-dependent kinases 4 or 6 (Cdk4/6; refs. 15, 16) . Consistent with this model, we have shown that in vivo abrogation of the kinase-dependent function of cyclin D1 is sufficient to render mice resistant to breast cancer initiated by ErbB2 (17), a phenotype that can be explained, at least in part, by a reduction in the number of cellular targets for ErbB2-mediated transformation (18) . These observations suggest that targeting cyclin D1/Cdk(4/6) is, in principle, a reasonable approach to treat breast cancers. Indeed, 2 recently developed Cdk(4/6) inhibitors have already entered clinical trials (19) . However, a better understanding of the metabolic and signaling pathways that are implemented in response to reduced levels of cyclin D1-associated kinase activity will be necessary to expand the therapeutic window and to confront the almost certain development of drug resistance.
Here, we describe the interplay between cellular processes that can affect proliferation in mammary epithelial cells (MEC) derived from kinase-deficient cyclin D1 KE/KE knockin mice. We found that cyclin D1 KE/KE mammary tissues are able to sustain increased proliferation in response to ErbB2, despite the insensitivity of mutant MECs to protumorigenic proliferative activity in the long term. These findings correlated with an upregulation of autophagy in cyclin D1 KE/KE mammary tissues along with a failure to upregulate markers of premature ErbB2-induced senescence. However, downregulation or blockade of autophagy in vitro had a detrimental effect on proliferation by increasing the senescence, suggesting that upregulation of autophagy observed in cyclin D1 KE/KE MECs may constitute a protective mechanism in response to reduced levels cyclin D1 activity. Thus, our findings suggest that blockade of autophagy may enhance the therapeutic effects of Cdk4/6 inhibitors in the treatment of breast cancer.
Materials and Methods

Mouse strains
Cyclin D1 KE/KE (17) and MMTV-ErbB-2 mice (strain TG. NK; ref. 20) were maintained in a C57BL/6 Â 129 mixed genetic background and genotyping was carried out as described elsewhere (17) . Ink4a/Arf-deficient animals have been previously described (21) . All animals used were treated humanely and in accordance with the Institutional Animal Care and Use Committee at Tufts Medical Center (Boston, MA) approved protocols.
Cell lines
Mammary glands harvested from Cyclin D1 þ/þ /Ink4a-Arf
and Cyclin D1 KE/KE /Ink4a-Arf À/À mice were mechanically disaggregated and digested with collagenase (Sigma) and hyaluronidase (Sigma). The resultant organoids were further digested in 0.25% trypsin-EDTA and Dispase/DNAse I and then filtered through a 40-mm mesh. Lineageþ cells (CD45þ, CD31þ, and Ter119þ) were immunomagnetically removed from freshly isolated cells using the Easysep mouse mammary stem cell enrichment kit (Stem Cell Technologies). Lineage (LinÀ) cells (mammary epithelial cells) were plated in Dulbecco's Modified Eagle's Medium/F-12 (1:1) culture medium (Invitrogen) supplemented with 2% FBS, 10 mg/mL insulin (Sigma), 5 ng/mL mouse EGF (Sigma), and 500 ng/mL hydrocortisone (Sigma). Cells were periodically passaged until the appearance of immortalized clones. Immortalized mouse mammary epithelial cells generated in this way were characterized using luminal and myoepithelial cell markers as described in Supplementary Fig. S4 and have not been used in previous publications. Human mammary epithelial cell lines (MCF10A and HMECs) were kindly provided by Dr. Charlotte Kuperwasser (Tufts University, Boston, MA). Since their original generation and description (22) (23) (24) , these cell lines have been extensively characterized and tested for their lineage and transformability phenotypes using multiple mammary epithelial cell markers (25, 26) .
Immunostaining
Mammary glands were fixed overnight in 4% paraformaldehyde/PBS. Sections (5 mm) were dewaxed, rehydrated, washed in PBS, and subjected to antigen retrieval by boiling in 10 mmol/L citrate buffer (pH 6.0). For frozen sections, tissues were fixed in 4% paraformaldehyde/PBS for 2 hours, followed by alternate washes in 50 mmol/L glycine and PBS. Tissues were then incubated in 20% sucrose/PBS overnight at 4 C and in 30% sucrose/PBS for 1 hour at room temperature before being embedded in optimum cutting temperature compound. For immunostaining, tissue sections were incubated overnight at 4 C with primary antibodies diluted in 2% bovine serum albumin/PBS. Secondary antibodies were applied for 1 hour at room temperature. Immune complex formation was detected through immunofluorescence using Alexa Fluor 488-and/or Alexa Fluor 546-conjugated antibodies (Invitrogen). Nuclei were stained with 4 0 , 6-diamidino-2-phenylindole (DAPI) whenever necessary (Sigma). Alternatively, sections were incubated with horseradish peroxidase-conjugated antibodies (Jackson) and immune complex formation visualized with 3,3 0 -diaminobenzidine method according to the manufacturer's instructions (Vector). Nuclei were counterstained with Mayer hematoxylin (Sigma). Antibodies used for immunostaining included are listed in the Supplementary Materials and Methods.
Transformation assays
Anchorage-independent growth of ErbB2/NeuT-infected cells (20 Â 10 3 ) was assayed by scoring the number of colonies formed in 0.4% agarose (with a 0.8% agarose underlay) after 3 weeks. When necessary, ErbB2/NeuT-infected cells (1 Â 10 6 ) were injected subcutaneously into nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice. Cells of different genotypes were injected into contralateral flanks of the same mouse. After 25 days, tumorharboring mice were euthanized, tumors removed, and weighed.
SA-b-Galactosidase activity
Detection of senescence-associated (SA)-b-galactosidase (b-gal) activity on tissue sections was carried out essentially as described (27, 28) . Briefly, cryosections (7 mm) were rehydrated and then incubated overnight at 37 C in staining solution (1 mg/mL 5-bromo-4-chloro-3-inolyl-b-D-galactoside (X-gal); 40 mmol/L citric acid/sodium phosphate buffer, pH 6.0; 5 mmol/L potassium ferrocyanide; 5 mmol/L potassium ferricyanide; 150 mmol/L NaCl; 2 mmol/L MgCl 2 ). Next day, sections were washed twice in PBS and mounted in glycerol. Alternatively, sections were costained with antibodies directed against Ki67 antigen.
Protein preparation and immunoblotting
Lin(À) MECs and organoid suspensions were lysed in E1A lysis buffer [250 mmol/L NaCl, 50 mmol/L HEPES pH 7.0, 5 mmol/L EDTA, 0.1% NP40, 1 mg/mL aprotinin, 50 mg/mL Pefabloc (Roche), 10 mg/mL leupeptin, 1 mmol/L DTT, 100 mmol/L sodium orthovanadate, 10 mmol/L b-glycerophosphate, 10 mmol/L sodium fluoride, and 2 mmol/L sodium pyrophosphate]. Immunoblotting was carried out essentially as described (17) . Antibodies used in this work are listed in the Supplementary Materials and Methods. Immunoblot analysis was carried out using horseradish peroxidase-conjugated donkey anti-rabbit or donkey anti-mouse antibodies (Jackson ImmunoResearch Laboratories). For cytokine antibody arrays (Mouse Cytokine Antibody Array, RayBiotech, Inc.), support membranes were incubated with protein lysates derived from organoids (300 mg) essentially as described in the manufacturer's instructions.
Statistical analysis
Numerical data are presented as mean AE SD or mean AE SEM of at least 3 independent experiments, and statistical significance between groups was identified using the 2-tailed Student t test.
Results
Cyclin D1
KE/KE mammary tissues sustain high, but temporally limited, proliferation in response to ErbB2
We have previously shown that cyclin D1 kinase activity is required for ErbB2-mediated breast cancer and the maintenance of mammary progenitors (17, 18) . While proliferation is very low in both cyclin D1 KE/KE (kinase activity deficient) and cyclin D1 þ/þ mammary epithelia in the absence of active ErbB2 (not shown), the question remained as to whether ErbB2-derived signals could lead to a proliferative response in the absence of the function of cyclin D1. Examination of ErbB2-expressing cyclin D1 KE/KE mammary tissues (cyclin D1 KE/KE /MMTV-ErbB2) from aged females ($ 6 months of age) revealed morphologic changes in both the epithelium and the stroma. Ducts from mutant glands appeared greater in diameter, with a higher number of epithelial nuclei per crosssection (Fig. 1A , panels and graph). In addition, staining with the myoepithelial cell marker a-smooth muscle actin (a-SMA) revealed a more prominent and disorganized layer of myoepithelium, composed of densely packed cells (Fig. 1A, right) . Stromal changes included prominent fibrosis surrounding the ducts (Fig. 1A , trichrome staining, middle). Of note, these morphologic changes were not observed in cyclin D1 KE/KE mammary tissues in the absence of ErbB2 (data not shown). Despite increased cellularity, staining with the proliferation marker Ki67 revealed few residual-positive cells in ErbB2-expressing cyclin D1 KE/KE mammary ducts. Interestingly, Ki67þ cells colocalized extensively with the myoepithelial marker a-SMA, a reflection of the differentiation phenotype previously described (ref. 18 ; Fig. 1B) . Collectively, these findings were indicative of an early expansion of ErbB2-expressing cyclin D1 KE/KE MECs, which nonetheless were unable to sustain proliferation late in life, probably due to aberrant differentiation into cells with myoepithelial features. Consistent with this, younger (3-month old) ErbB2-expressing cyclin D1 KE/KE mammary tissues displayed high levels of proliferation, similar to the levels observed in ErbB2-expressing cyclin D1 þ/þ mammary tissues but much higher than the levels observed in mammary tissues lacking the ErbB2 transgene ( Fig. 1C and not shown). Importantly, ectopic proliferation observed in mutant mammary glands was accompanied by reduced levels of phosphorylation at Serine-780 of pRb, a cyclin D-dependent phosphorylation event (17) , as well as reduced levels of the E2F targets cyclin A and cyclin E (Supplementary Fig. S1A and S1B). These findings indicate that pRb-independent proliferation, although temporally limited, can still take place in mutant mammary tissues in response to ErbB2.
Upregulation of autophagy in cyclin D1
KE/KE mammary tissues Given the central role of cyclin D1 as an integrator of growthpromoting signals that can also have an impact on autophagy (5), we speculated that this process might be deregulated in mutant MECs, perhaps explaining the proliferative changes in ErbB2-expressing mammary tissues described above. To test this hypothesis, we took advantage of an antibody that recognizes the cleaved form of LC3 (microtubule-associated light chain 3), which has been used as a reliable marker for autophagy using immunohistochemistry on a variety of tissues (29) (30) (31) . Cleavage of LC3 is the first step in a process that allows the protein to be lipidated and incorporated into the membrane of autophagosomes (2) . As shown in Fig. 2A , levels of cleaved LC3 were upregulated in cyclin D1 KE/KE mammary tissues compared with cyclin D1 þ/þ controls, and the intensity of staining was further increased in ErbB2-expressing cyclin D1 KE/KE mammary tissues. A similar upregulation of this marker was observed in protein lysates obtained from freshly isolated mutant MECs [Lin(À) fraction; Fig. 2B ). To further support our findings, we studied mammary tissues at the ultrastructural level using transmission electron microscopy. Although visualization of classical autophagosomes was challenging, this analysis revealed signs of prominent intracellular digestion activity, including the presence of abundant vesicles with variable degrees of electron density consistent with lysosomes, autolysosomes, and residual bodies in cyclin D1 KE/KE but not cyclin D1 þ/þ mammary tissues (Supplementary Fig. S2 and data not shown). Taken together, our findings indicate that mammary tissues deficient in cyclin D1 activity show signs of increased autophagic activity.
Cyclin D1 KE/KE mammary tissues display reduced ErbB2-mediated senescence Premature senescence is a potent barrier against unscheduled proliferation of early transformed cells (12, 32) . Recently, Young and colleagues have shown that autophagy can be induced as an effector mechanism during Ras-induced senescence in vitro. Inhibition of autophagy in this setting resulted in a failure to activate a senescence program (11) . Given the observation that ErbB2-expressing cyclin D1 KE/KE mammary tissues display an upregulation of autophagy markers and are unable to develop tumors, we speculated that increased autophagy might reflect or facilitate ErbB2-induced senescence in mutant tissues. Surprisingly, ErbB2-expressing cyclin D1 KE/KE mammary tissues failed to upregulate SA-bgalactosidase activity compared with preneoplastic ErbB2-expressing cyclin D1 þ/þ controls (Fig. 3A) . Of note, robust b-Gal staining was also detected in cyclin D1
þ/þ / MMTV-ErbB2 tumor lesions (Fig. 3A, middle) . As expected, however, b-Galþ regions and Ki67 staining did not colocalize in ErbB2-derived tumors ( Supplementary Fig. S3A ), perhaps indicating that proliferative regions evolved following escape from senescence. We also confirmed that senescence observed in ErbB2-expressing cyclin D1 þ/þ preneoplastic tissues was restricted to the ductal epithelium ( Supplementary Fig. S3B ). The failure to undergo senescence observed in ErbB2-expressing cyclin D1 KE/KE mammary tissues was corroborated by staining for histone 3 trimethylated at lysine 9 (H3K9me3), a marker for heterochromatin formation and a hallmark of senescence (Fig. 3B) . As an additional confirmation of our findings, we analyzed the expression of factors that are produced and secreted by senescent cells (32) (33) (34) (35) . Quantitative real time (RT)-PCR using mammary tissues or purified mammary epithelial cells (Lin(À) fractions) from ErbB2-expressing cyclin D1 KE/KE mammary glands revealed a failure to upregulate the expression of selected factors ( Fig. 3C and Supplementary Fig. S3C ). Moreover, cytokine array analyses of protein lysates from ErbB2-expressing cyclin D1 KE/KE mammary tissues revealed reduced levels of interleukin-6 (IL-6), another senescence-associated secreted factor (36; Supplementary Fig. S3D ). Furthermore, although senescence observed in ErbB2-expressing cyclin D1 þ/þ mammary tissues was not accompanied by an induction of p16 Ink4a or p19 Arf as observed in other systems (37, 38) , we did observe a relative increase in the levels of p18
INK4c and p27
Kip1 in ErbB2-expressing cyclin D1 þ/þ mammary tissues compared with the ErbB2-expressing cyclin D1 KE/KE counterparts ( Supplementary Fig. S3E ). Importantly, we were unable to detect differences in apoptosis in tissues derived from ErbB2-expressing cyclin D1 þ/þ or cyclin D1 KE/KE mice (Supplementary Fig. S3F ). Taken together, despite evidence that autophagy upregulation may be required for the proper orchestration of oncogene-induced senescence, our findings indicate that these processes can occur in a mutually exclusive manner in mammary tissues that are deficient in cyclin D1 function. Supplementary Fig. S4B ), with bromodeoxyuridine (BrdUrd) incorporation and cell-cycle profile analyses revealing a small albeit significant reduction of KE/Ink4(À) cells undergoing cell division (Supplementary Fig. S4C ). Importantly, we were unable to detect any difference in the proportion of cells undergoing apoptosis and, as expected, senescent cells were only sporadically detectable in both cell lines (not shown). The proliferation defect observed in KE/Ink4(À) MECs was improved but did not reach wild-type levels following transduction of ErbB2/NeuT ( Supplementary Fig. S4D ), a fact that was also reflected in their poor colony formation ability (Supplementary Fig. S4E ). These findings stand in contrast with the robust proliferation of ErbB2-expressing cyclin D1 KE/KE cells in vivo (Fig. 1C) and may reflect contributions from the microenvironment that promote aberrant proliferation in the presence of ErbB2. Nevertheless, even taking the proliferation deficiency into account, ErbB2/NeuT-transduced KE/Ink4(À) MECs showed a disproportionately reduced ability to form colonies in soft agar ( Supplementary Fig. S4F ) or tumors after subcutaneous injection into NOD/SCID mice ( Supplementary Fig. S4G ). Thus, similar to our in vivo observations, the KE mutant profoundly impairs transformation in MECs without overtly altering senescence or apoptosis, making this system suitable for analyzing the dynamics of autophagy in mutant MECs.
KE/Ink4(À) MECs retain increased rates of autophagy
As a first approach to study autophagy in vitro, we determined LC3 protein levels in immortalized MECs. Following cleavage, LC3 becomes lipidated (LC3-II) and localizes to autophagosome membranes, a modification that allows it to be distinguished from the soluble form (LC3-I; ref. 40) . As shown in Fig. 4A , LC3-II and to a lesser extent Beclin-1 protein levels, were increased in KE/Ink4(À) MECs. However, LC3-II did not increase further following expression of ErbB2/ NeuT (Supplementary Fig. S5A ).
As LC3-II accumulation could also reflect a defect in autophagosome-lysosome fusion (40), we also checked the levels of p62/SQSTM1, a protein that is normally degraded through autophagy (10) . As expected, levels of p62/SQSTM1 were reduced in KE/Ink4(À) MECs (Fig. 4A) , an indication of increased autophagic activity. In addition, blockade of autophagosome-lysosome fusion using chloroquine led to the simultaneous accumulation of LC3-II and p62/SQSTM1 in both cell lines, although LC3-II reached higher levels in KE/Ink4(À) MECs (Fig. 4B) (Fig. 4C, top graph) , the number of double-positive autophagosomes per cell was dramatically increased in KE/Ink4(À) MECs (Fig. 4C , bottom graph). As expected from normal autophagosome maturation, the number of autophagosome-containing cells and the number of autophagosomes per cell decreased over time, with concomitant increase in red-only autolysosomes. However, the proportion of KE/Ink4(À) MECs containing autolysosomes was still higher than WT/Ink4(À) MECs (Fig. 4D) . Importantly, autolysosomes were invariably positive for endocytosed dextran that labels lysosomes ( Supplementary Fig. S5B ), confirming autophagosomelysosome fusion. Taken together, these data are consistent with a basal upregulation of autophagy in immortalized cyclin D1 KE/KE MECs. We next studied the proliferative and tumorigenic effects of autophagy downregulation in MECs. Unexpectedly, shRNAmediated knockdown of Beclin-1 did not lead to a reduction of LC3-II or changes in proliferation ( Supplementary Fig. S6A and S6B). Furthermore, Beclin-1-depleted KE/Ink4(À) cells were still able to upregulate LC3-II in response to mTORC1 inhibition ( Supplementary Fig. S6C ). Thus, in contrast to other systems reported in the literature, these experiments reveal a surprising ability of MECs to induce autophagosome formation even in the context of profoundly reduced levels of Beclin-1.
Unlike Beclin-1, shRNA-mediated downregulation of ATG5 resulted in a dramatic inhibition of autophagy, reflected in the almost undetectable levels of LC3-II and concomitant accumulation of p62/SQSTM1 (Fig. 5A) . Surprisingly, disrupting autophagosome formation led to impaired proliferation (Fig. 5B) . However, while knocking down ATG5 in WT/Ink4 (À) MECs resulted in a modest increase in both apoptosis and senescence, ATG5-deficient KE/Ink4(À) MECs showed a pronounced senescence response (Fig. 5C and D) . Accordingly, ATG5 depletion in ErbB2/NeuT-expressing MECs further reduced their ability to be transformed (Fig. 5E ). These data suggest that the increased autophagy observed in mutant MECs is required to sustain proliferation and survival in the context of reduced cyclin D1 function. To extend our findings to more therapeutically relevant human models, we first set out to reduce the expression of cyclin D1 in telomerase-immortalized HMECs (22) . Knockdown of cyclin D1 using 3 different shRNAs led to dramatic proliferation impairment (Supplementary Fig. S7A ) that correlated with the degree of cyclin D1 reduction and hypophosphorylation of pRB at Ser-780 (Fig. 6A, see shRNAs  #1 and 16) . Importantly, cyclin D1 reduction was also accompanied by an upregulation of LC3-II and a reduction of p62/SQSTM1 (Fig. 6A) . Unlike KE/Ink4(À) MECs, however, the proportion of senescent cells was greater in cyclin D1-depleted HMECs (Fig. 6B ). Because differences in senescence between KE/Ink4(À) and D1-depleted HMECs could reflect the ability of kinase independent functions of cyclin D1 to repress induction of senescence, we next wanted to know whether the pharmacologic inhibition of Cdk4/6 in HMECs could better reproduce the phenotypes observed in KE/Ink4(À) cells. To this end, we took advantage of the highly specific Cdk4/6 inhibitor PD0332991 (19) . Although PD0332991 treatment did not elicit a significant apoptotic response (not shown), the proportion of HMECs in S to G 2 -M was significantly reduced by the treatment (Supplementary Fig. S7B ). To visualize autophagy, HMECs were first transfected with the LC3-Cherry-EGFP construct and then treated with 0.5 mmol/L PD0332991 or vehicle (dimethyl sulfoxide; DMSO) for 24 or 72 hours. As shown in Fig. 6C (right) , the number of autophagosomes (vesicles exhibiting both red and green signals) per cell increased significantly following drug treatment. We confirmed these observations by comparing the endogenous levels of LC3-II in drug-or vehicle-treated cells (Fig. 6C, left) . The proportion of senescent cells also increased after PD0332991 treatment, although to a much lesser extent compared with cyclin D1-depleted HMECs (Fig. 6D) . Thus, proliferation arrest achieved through either genetic depletion of cyclin D1 or inhibition of Cdk4/6 activity is accompanied by an early induction of autophagy in HMECs.
We next tested the combined effects of autophagy downregulation and Cdk4/6 inhibition in HMECs. Similar to what we observed in KE/Ink4(À) MECs (Fig. 5) , knockdown of ATG5 in HMECs increased the proportion of senescent cells, a response that was further exacerbated by PD0332991 treatment (Fig. 7A and B) . Thus, contrary to recent reports describing autophagy as an effector mechanism of senescence in fibroblasts (11), autophagy reduction in MECs can activate the senescence program. Moreover, these findings lend further support to the concept that autophagy functions primarily as a proproliferative process in MECs, and also suggest that the combined use of inhibitors of autophagy and Cdk4/6 might represent a promising therapeutic approach to treat breast cancers. To explore this idea, immortalized HMECs and ErbB2/NeuT-expressing MCF10A, a tumorigenic cell line, were treated with chloroquine, PD0332991 (PD), or a combination of both compounds. Importantly, concentrations of single drugs used in these experiments were kept at a minimum to detect enhancing effects when used in combination. As shown in Fig. 7C , combined use of chloroquine and PD0332991 led to a reduction in proliferation compared with cells that were untreated or treated with a single drug. Furthermore, the ability of ErbB2/NeuT-expressing MCF10A cells to form colonies in soft agar was significantly reduced following chloroquine or PD0332991 treatment, an effect that was further exacerbated when cells were treated with both compounds (Fig. 7D) .
Discussion
In the present work, we sought to identify and characterize cellular processes that are altered in MECs displaying reduced cyclin D1 activity in an effort to better understand the biologic effects of pharmacologic Cdk4/6 inhibition. To this end, we used the cyclin D1 KE/KE knockin mouse as our primary model (17, 18) . Surprisingly, cyclin D1 KE/KE mammary tissues were initially able to sustain aberrant proliferation in response to ErbB2, despite impaired pRb phosphorylation. Because many growth-promoting signals (including those dependent on ErbB2) can increase the levels or activity of cyclin D1 (14, 42) and, at the same time, inhibit autophagy (5, 43), we reasoned that autophagy might be upregulated in cyclin D1 KE/KE mammary tissues to compensate for reduced cyclin D1 activity. Indeed, using several approaches, we show here that cyclin D1 KE/KE mammary tissues display signs of increased autophagic activity. This increase in autophagy in the presence of impaired pRb phosphorylation is consistent with a recent study linking pRb's E2F binding function to autophagy induction (44) . However, other studies have linked the pRb-E2F interaction to autophagy suppression (45, 46) , indicating that these functions may be context dependent.
Importantly, unlike recent reports indicating that autophagy upregulation is required for oncogene-induced senescence (11), ErbB2-expressing cyclin D1 KE/KE mammary epithelium displayed a significant reduction in senescence while retaining increased levels of autophagy, suggesting that these processes may be regulated differently in mutant mammary glands. Given the high proliferative fraction and the lack of senescence and apoptosis in ErbB2-expressing cyclin D1 KE/KE mammary tissues, it is surprising that mutant animals display a profound lack of transformation as they age. On the basis of the observed increase in myoepithelial cells in mutant mammary glands and the reduction in progenitor cells (18) , we surmise that mutant MECs lacking cyclin D1 activity undergo terminal, albeit aberrant, differentiation even in the presence of activated ErbB2, thereby avoiding neoplastic conversion. However, we cannot exclude stromal defects or paracrine effects resulting from, for example, senescence-associated secreted factors, which are consistently reduced in mutant glands. Future studies using transplantation of MECs and stromal cells, alone or in combination, will be required to fully understand the fate of ErbB2-expressing cyclin D1 KE/KE mammary MECs. To better understand the role of autophagy in cyclin D1 KE/KE MECs, we established a cell culture system that mimicked many of the in vivo properties of these cells. Consistent with the in vivo data, high rates of autophagy were retained in immortalized cyclin D1 KE/KE MECs. In keeping with its prosurvival function, downregulation of autophagy in these cells worsened cell proliferation through an exacerbation of senescence. It is important to note that, despite initial observations pointing to a role for autophagy in tumor suppression (3, 10, 47, 48) , evidence from more refined animal models indicates that abrogation of autophagy in selected tissues can impair tumor initiation (49) .
How do we reconcile these seemingly opposing functions of autophagy during tumorigenesis? One possibility is that upregulation of autophagy does have a long-term tumor suppressive effect in ErbB2-expressing mammary epithelia by way of preventing the accumulation of protein aggregates, damaged organelles, and reactive oxygen species (ROS; ref. 10). Accordingly, abrogation of autophagy in vivo may favor a mutagenic environment that would allow the acquisition of additional genetic events necessary to escape ErbB2-induced senescence and ensure tumor evolution. In contrast, acute disruption of autophagy in vitro, with the consequent rapid accumulation of cellular damage, would be expected to activate senescence unless other tumor suppressive pathways are also disrupted.
The data presented here might also point to unappreciated relationships between cyclin D1 function, autophagy and metabolism. The coexistence of proliferation and autophagy in ErbB2-expressing cyclin D1 KE/KE mammary tissues suggests that despite the ability of the mutant protein to sustain a ErbB2-dependent proliferative response, the noncatalytic functions of cyclin D1 are not sufficient to suppress autophagy in vivo. In this scenario, functional cyclin D1/Cdk(4/6) complexes may act as a nexus to indicate both growth factor and nutrient proficiencies appropriate for a proliferative response. In the context of inactive cyclin D1/Cdk(4/6) complexes, induction of autophagy and proliferation may represent an attempt to respond to growth promoting signals in the perceived absence of metabolic substrates. Further work will be necessary to test this hypothesis.
In summary, highlighting the crucial position of cyclin D1 downstream of many growth-promoting signals, abrogation of cyclin D1 activity triggers the activation of autophagy in both murine and human MECs. Moreover, suppression of autophagy together with cyclin D1-dependent kinase inactivation in immortal and transformed human MECs leads to increased senescence or reduced proliferation and transformation. Therefore, the functional connection between cyclin D1 and autophagy may be exploited through combinatorial pharmacologic modulation of Cdk4/6 activity and the autophagy response to more efficaciously treat breast cancer.
